GENETICALLY MODIFIED ADENOVIRAL VECTOR CONTAINING A HETEROLOGOUS RGD PEPTIDE IN THE HI LOOP OF THE FIBER KNOB IMPROVES GENE TRANSFER TO VASCULAR ENDOTHELIAL CELLS IN ORGAN CULTURE

1999 ◽  
Vol 67 (7) ◽  
pp. S206
Author(s):  
Guadalupe Bilbao ◽  
Juan Contreras ◽  
Victor Krasnykh ◽  
Galina Mikheeva ◽  
Igor Dmitriev ◽  
...  
1996 ◽  
Vol 62 (8) ◽  
pp. 1085-1089 ◽  
Author(s):  
Anna F. Merrick ◽  
Lorna D. Shewring ◽  
Greta J. Sawyer ◽  
Kenth T. Gustafsson ◽  
John W. Fabre

Hypertension ◽  
2000 ◽  
Vol 36 (suppl_1) ◽  
pp. 691-691
Author(s):  
Stuart A Nicklin ◽  
Steve J White ◽  
Andrew H Baker

75 Current gene transfer vectors are extremely limited for selective vascular cell delivery due to their promiscuous tropism and low efficiency of gene delivery to the vasculature. We have sought to improve the efficiency of gene transfer to vascular endothelial cells using phage display. Using bio-panning on whole cells, we have isolated a panel of 60 7-mer peptides that have the ability to bind endothelial cells but not to non-endothelial cells including vascular smooth muscle cells and hepatocytes. One candidate peptide was cloned upstream of a single chain antibody (scFv) generated against the knob domain of adenovirus type 5, expressed in bacteria and purified. While the scFv alone inhibited adenoviral fiber-dependent infection of all cell types tested (to >95% in hepatocytes), the scFv-peptide fusion mediated selective infection into endothelial cells without infection into non-endothelial cells types. Furthermore, the level of infection achieved in endothelial cells was 15 fold higher than that achieved with fiber-mediated gene transfer alone. We have additionally isolated 15 individual peptides that have the ability to target the endothelial leptin-like oxidised LDL receptor (LOX-1), a receptor highly expressed in endothelial cells in hypertensive models and in atherosclerotic lesions, by phage bio-panning on cells ectopically expressing the LOX-1 receptor. Candidate peptides mediated significantly higher binding to LOX-1 expressing cells compared to LOX-1 negative cells. Their ability to re-target adenoviral gene transfer is being tested. Our results demonstrate that small, novel peptides isolated by phage display have the ability to retarget gene transfer selectively and efficiently to vascular endothelial cells. This has important implications for targeting gene transfer to endothelial cells for molecular and therapeutic protocols in hypertension.


Circulation ◽  
2000 ◽  
Vol 102 (2) ◽  
pp. 231-237 ◽  
Author(s):  
Stuart A. Nicklin ◽  
Steve J. White ◽  
Sarah J. Watkins ◽  
Robert E. Hawkins ◽  
Andrew H. Baker

1995 ◽  
Vol 9 (1) ◽  
pp. 71-79 ◽  
Author(s):  
R.A. Kotnis ◽  
M.M. Thompson ◽  
S.L. Eady ◽  
J.S. Budd ◽  
P.R.F. Bell ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5533-5533
Author(s):  
Yucheng Tang ◽  
Jonathan Maynard ◽  
Hakan Akbulut ◽  
Phyllis-Jean Linton ◽  
Albert B. Deisseroth

Abstract In order to develop a method to overcome the immune tolerance of cancer, we have designed an Ad-sig-TAA/ecdCD40L adenoviral vector vaccine for the in vivo activation and tumor antigen loading of dendritic cells (DCs). Subcutaneous (sc) injection of the Ad-sig-TAA/ecdCD40L adenoviral vector results in the secretion for 10 days from the vector infected cells of a fusion protein composed of a fragment of a tumor associated antigen (TAA) fused to the extracellular domain (ecd) of the CD40 ligand (CD40L). CD40L is a homo-trimeric protein normally found on B cells and helper CD4+ T cell lymphocytes. All of the sequences necessary to stabilize this trimeric structure of the protein are contained within the ecd of the CD40L protein. The binding of the TAA/ecdCD40L protein to DCs induces migration of these DCs to the regional lymph nodes. These DCs carry fragments of TAA bound to surface MHC Class I molecules. We have shown that the Ad-sig-TAA/ecdCD40L vector strategy can induce a cellular and humoral immune that persists for over a year indicating that a durable memory response is generated. We showed that sc injections of the Ad-sig-rH2N/ecdCD40L vector in rH2N.Tg mice induces a cellular and humoral immune response against the rat Her-2-Neu (rH2N) antigen which is associated with breast cancer. We showed that the sc injection of the Ad-sig-rH2N/ecdCD40L adenoviral vector in a rH2N.Tg transgenic mouse induced resistance to the growth of rH2N positive cancer cells in mice previously anergic to the rH2N antigen. We demonstrated that the sc injection of the Ad-sig-hMUC-1/ecdCD40L vector suppressed the growth of tumor cells positive for the human MUC-1 (hMUC-1) antigen in hMUC-1.Tg mice which were previously anergic to the hMUC-1 antigen. The sc injection of the Ad-sig-hMUC-1/ecdCD40L vector followed by sc injection of two booster injections of the hMUC-1/ecdCD40L protein induced high levels of hMUC-1 specific tumor infiltrating effector CD8 positive T cells and hMUC-1 antibodies which bound to human breast and prostate cancer cells. In addition, we recently showed that the Ad-sig-TAA/ecdCD40L strategy could be used to activate a cellular and humoral immune response against Annexin A1 (AnxA1), which is a marker uniquely displayed on the luminal membrane of tumor vascular endothelial cells but not on the luminal membrane of vascular endothelial cells of normal tissue. The subcutaneous injection of the Ad-sig-AnxA1/ecdCD40L vector suppressed the growth of AnxA1 negative tumor cells in a syngeneic mouse tumor model. This vector prime/protein boost vaccination was found to induce increased levels of effector CD8 positive T cells in the target tumor. These effector T cells were shown express increased levels of the genes encoding the CCR5 chemokine receptor and the CCL3 chemokine ligand which promote the infiltration of antigen specific effector T cells in the target tumor tissues. The response to cancer vaccines is often reduced in older individuals in part due to an intrinsic functional defect in CD4 cells. The Ad-sig-TAA/ecdCD40L vaccine may circumvent this defect because we have shown that the induction of the immune response is CD4 independent. These data suggest that this vector prime-protein boost vaccination strategy will be useful in the reduction of the frequency of recurrence following initial therapy for a wide variety of neoplastic diseases.


2001 ◽  
Vol 4 (3) ◽  
pp. 174-181 ◽  
Author(s):  
Stuart A. Nicklin ◽  
Hildegard Buening ◽  
Kate L. Dishart ◽  
Mahesh de Alwis ◽  
Anne Girod ◽  
...  

2006 ◽  
Vol 235 (1) ◽  
pp. 105-114 ◽  
Author(s):  
Karine Bollérot ◽  
Daisuke Sugiyama ◽  
Virginie Escriou ◽  
Rodolphe Gautier ◽  
Samuel Tozer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document